Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)
Recruitment status was: Recruiting
The purpose of this clinical trial is to establish the safest doses for the combination of a farnesyl transferase inhibitor, R115777 plus topotecan in patients with advanced solid tumors, previously treated or beyond standard therapy of clinical benefit. Maximum tolerated dose, dose limiting toxicity and the activity of this combination will be assessed.
This chemotherapy regimen is a two-pronged attack at the way cancer cells replicate. R115777 is a compound that may inhibit cancer cell growth by interfering with the p21 ras oncogene, while topotecan, a topoisomerase-1 inhibitor, works on cancer cells not subject to control by the ras oncogene. Animal studies suggest that the combination may be synergistic. Another advantage is that R115777 can be taken by mouth.
|Cancer||Drug: R115777 (farnesyl transferase inhibitor) Drug: Topotecan||Phase 1|
|Study Design:||Primary Purpose: Treatment|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00006199
|Contact: Anita Tierney||1-212-263-2173|
|United States, New York|
|NYU Cancer Institute||Recruiting|
|New York, New York, United States, 10016|
|Contact: Anita Tierney 212-263-2173|